GW Pharmaceuticals PLC (GWPH)

124.92
1.10 0.90
NASDAQ : Health Care
Prev Close 126.06
Open 125.60
Day Low/High 122.61 / 127.45
52 Wk Low/High 35.83 / 120.99
Volume 966.47K
Avg Volume 630.20K
Exchange NASDAQ
Shares Outstanding 21.77M
Market Cap 2.34B
EPS -3.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Jim Cramer's Top Takeaways: GW Pharmaceuticals, Apple, Align Technology

Jim Cramer's Top Takeaways: GW Pharmaceuticals, Apple, Align Technology

Cramer continues to back Apple and says Align Technology is a stock to buy now.

Jim Cramer's 'Mad Money' Recap: Why Tonight's Debate Doesn't Really Matter

Jim Cramer's 'Mad Money' Recap: Why Tonight's Debate Doesn't Really Matter

Investors hate uncertainty, Cramer says, but uncertainty creates bargains.

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.

GW Pharmaceuticals (GWPH) Stock Soars on Positive Trial Results, Piper Jaffray Bullish

GW Pharmaceuticals (GWPH) Stock Soars on Positive Trial Results, Piper Jaffray Bullish

GW Pharmaceuticals (GWPH) said on Monday its seizure drug epidiolex had positive results in a late-stage clinical trial.

Stephen King's Maximum Oversold (by Midweek)

And we'll get FOMC and BoJ then.

'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position

'Mad Money' Lightning Round: Abbvie Is a Great Long-Term Position

Cramer is sticking with International Paper and likes Advanced Micro Devices.

Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks

Jim Cramer's 'Mad Money' Recap: Why You Shouldn't Be Jumping In and Out of Stocks

This is not the time to sell in a panic, Cramer says.

4 Companies Likely to Benefit From Widening Legalization of Marijuana

4 Companies Likely to Benefit From Widening Legalization of Marijuana

The marijuana market is heating up as marijuana usage for medical and recreational purposes gains legitimacy.

GW Pharmaceuticals (GWPH) Closed Higher on Takeover Speculation

GW Pharmaceuticals (GWPH) Closed Higher on Takeover Speculation

GW Pharmaceuticals (GWPH) reportedly hired Morgan Stanley after it was approached by several companies about a possible takeover.

'Mad Money' Lightning Round: Weight Watchers Is Not for Me

'Mad Money' Lightning Round: Weight Watchers Is Not for Me

Cramer says sell Stryker and buy Zimmer Biomet, and take Randgold over Barrick Gold.

Jim Cramer's 'Mad Money' Recap: I Can't Figure Out the Consumer

Jim Cramer's 'Mad Money' Recap: I Can't Figure Out the Consumer

The economy needs consumers to buy, buy, buy but so far consumers have been all over the map, Cramer says.

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Nasdaq-traded marijuana stocks are undervalued as investors remain skittish and the use of drugs produced by these biopharmaceutical companies have not been widely adopted.

Consumer Staples And Utilities Sectors Avoided Volatility in Brexit Aftermath

Consumer Staples And Utilities Sectors Avoided Volatility in Brexit Aftermath

Investors should stick with buying stocks in the utilities and consumer staples sectors, which rose higher in the aftermath of the Brexit vote and avoided the massive volatility.

Janney Says Sell GW Pharma Despite Marijuana-Derived Drug Success In Seizures

Janney Says Sell GW Pharma Despite Marijuana-Derived Drug Success In Seizures

Shares of GW Pharmaceuticals are on the rise after the company announced this morning positive Phase 3 results for its Epidiolex for the treatment of Lennox-Gastaut syndrome, or LGS.

GW Pharmaceuticals (GWPH) Moving On Heavy Volume In The Pre-Market Hours

GW Pharmaceuticals (GWPH) Moving On Heavy Volume In The Pre-Market Hours

Trade-Ideas LLC identified GW Pharmaceuticals (GWPH) as a pre-market mover with heavy volume candidate

GW Pharma Marijuana Drug Confirms Seizure Benefit in Second Pivotal Trial

GW Pharma Marijuana Drug Confirms Seizure Benefit in Second Pivotal Trial

GW Pharmaceuticals announced positive results Monday from a second, pivotal clinical trial involving children with a severe form of epilepsy treated with its experimental marijuana-based drug.

Brexit Vote Leaves Investors Cautious

Folks are anxious, dying to be bullish yet also curbing their enthusiasm.

Here’s How You Should Invest If Gary Johnson Makes It to the White House

Here’s How You Should Invest If Gary Johnson Makes It to the White House

It may not be the likeliest of scenarios, but if Gary Johnson becomes president of the United States, investors might want to shift some money around. Here's how.

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan

'Brexit' will be Cramer's focus, along with company earnings and Fed Chair Janet Yellen's congressional testimony.